Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...
New research reveals these medications impact everything from heart health to restaurant menus.
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity ...
Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback